Use of ^99mTc-HMPAO in Estimating the Antihypertensive Therapy Impact on the Cerebral Perfusion in Patients with Arterial Hypertension Associated with Diabetes Mellitus Type 2

Abstract:

The article is devoted to the estimation of the impact of hypotensive therapy on the state of cerebral perfusion in patients with AH, associated with type 2 DM using ^99mTc-HMPAO brain SPECT. It has been shown that the signs of the brain hypoperfusion and reduced cerebrovascular reserve are observed in patients with AH in combination with type 2 DM even when focal neurological symptoms are absent. Using ^99mTc-HMPAO brain SPECT it has been found that carvedilol therapy of about 6 months has a positive effect on the cerebral perfusion and cerebrovascular reserve status in these patients.

• Periodical: Advanced Materials Research (Volume 1084)
• Pages: 487-491
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1084.487
• Online since: January 2015
• Authors: Irina Yu. Efimova, Nataliya V. Belokopytova, Nataliya Yu. Efimova*, Yuriy B. Lishmanov
• Keywords: ^99mTc-HMPAO, Arterial Hypertension, Brain Perfusion, Diabetes Mellitus, SPECT

References

[1] V.B. Mychka, V.V. Gornostaev, I.E. Chazova, Cardiovascular complications of diabetes mellitus type 2, Kardiologiya (in Russian). 4 (2002) 73-77.

[2] M.V. Shestakov, Arterial hypertension and diabetes mellitus: mechanisms of development and tactics of treatment, Saharniy Diabet (in Russian). 3 (1999) 19-23.

[3] U.V. Zimin, Arterial hypertension in diabetes mellitus: pathogenesis and treatment characteristics, Ter. Archive (in Russian). 10 (1999) 15-20.

[4] I. Yu. Efimova, I.A. Astanina, M.V. Kolodina, Cerebral microcirculation and structural changes in the brain with essential hypertension, Klinicheskaya medicina (in Russian). 12 (2004) 16-19.

[5] H. Chair, J.R. Sowers, G.L. Baumbach, National high blood pressure education program working groop report on hypertension in diabetes, Hypertension. 23 (1994) 145-158.

DOI: 10.1161/01.hyp.23.2.145

[6] O.D. Ostroumova, A.M. Batutina, V.G. Kukes, A.A. Zykova, A.G. Abrosimov, Diabetes and hypertension: the possibility of using beta-blockers, Kardiovaskulyarnaya terapiya i profilaktika (in Russian). 1 (2002) 76-82.

[7] L. Landsberg, Insulin resistance, energy balance and sympathetic nervous system activity, Clin. Exp. Hypertens. 12(5) (1990) 817-830.

[8] J.R. Sowers, P.R. Standley, J.L. Ram, S. Jacober, L. Simpson, K. Rose, Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis, Am.J. Hypertens. 6(7) (1993) 260S-270S.

DOI: 10.1093/ajh/6.7.260s

[9] G.L. Baumbach, D.D. Heistad, Remodeling of cerebral arterioles in chronic hypertension, Hypertension. 13(6) (1989) 968-972.

DOI: 10.1161/01.hyp.13.6.968

[10] J.M. Chillon, G.L. Baumbach, Effects of an angiotensin-converting enzyme inhibitor and a ß-blocker on cerebral arterioles in rats, Hypertension. 33(3) (1999) 856-861.

DOI: 10.1161/01.hyp.33.3.856

[11] A. Ficzere, A. Valikovics, B. Fulesdi, A. Juhász, I. Czuriga, L. Csiba, Cerebrovascular reactivity in hypertensive patients: a transcranial Doppler study, J. Clin. Ultrasound. 25(7) (1997) 383-389.

DOI: 10.1002/(sici)1097-0096(199709)25:7<383::aid-jcu6>3.0.co;2-6

[12] L.A. Geraskina, Z.A. Suslina, A.V. Fonyakin, T.N. Sharypova, Cerebral perfusion in patients with arterial hypertension and chronic forms of cerebral vascular pathology, Ter. Archive (in Russian). 12 (2003) 32-36.

[13] G. Rodriguez, F.D. Nobili, M.A. Celestino, S. Francione, G. Gulli, K. Hassan, S. Marenco, G. Rosadini, R. Cordera, Regional cerebral blood flow and cerebrovascular reactivity in IDDM, Diabetes Care. 16(2) (1993) 462–468.

DOI: 10.2337/diacare.16.2.462

[14] Diabetes and Cardiovascular Disease: Time to act. International Diabetes Federation, (2001).

[15] V.I. Makolkin, Application of modern β-blockers for hypertension in patients with metabolic syndrome, Arterial hypertension (in Russian). 11 (3) (2005) 149-154.

[16] S. Jacob, K. Rett, E.J. Henriksen, Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Amer. J. Hypertens. 11(10) (1998) 1258-1265.

DOI: 10.1016/s0895-7061(98)00141-1

[17] N.L. Afanasyeva, V.F. Mordovin, N.Y. Efimova, G.V. Semke, I. Yu. Efimova, Antihypertensive efficacy and cerebroprotective of beta-blocker of metoprolol, Russian Journal of Cardiology (in Russian). 51 (2005) 60-64.

[18] V.B. Mychka, V.B. Sergienko, V.V. Gornostaevet, I.M. Dvoskina, I.E. Chazova, Bisoprolol influence on cerebral perfusion in patients with metabolic syndrome, Arterial hypertension (in Russian). 9 (5) (2003) 151-154.

DOI: 10.18705/1607-419x-2003-9-5-160-163